Brainstorm Cell Therapeutics | BCLI - Operating Profit


Brainstorm Cell Therapeutics reported $-2.05M in Operating Profit for its fiscal quarter ending in March of 2026.





Operating Profit Change Date
Alterity Therapeutics Limited AUD -8.07M 302.4K Dec/2025
Biogen USD -243.8M 758.1M Jun/2026
Brainstorm Cell Therapeutics USD -2.05M 198K Mar/2026
Cipla INR 8.88B 2.74B Jun/2026
Clal Biotechnology ILS -1.74M 7.46M Dec/2022
Compugen USD -9.02M 65.06M Mar/2026
CSL USD 2.64B 1.97B Dec/2025
Cytokinetics USD -179.17M 2.05M Jun/2026
Gilead Sciences USD 3.85B 1.17B Jun/2026
Grifols EUR 320.55M 91.01M Dec/2025
Halozyme Therapeutics USD -63.72M 1.95M Jun/2026
Mesoblast USD -30.96M 11.14M Dec/2025